ClinicalTrials.gg
RecruitingNCT07213323PROBIO-GLP1Updated Aug 19, 2026

Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment

An interventional study of Probiotics (Natural product) and Placebo in Obesity &Amp; Overweight and Digestive Disorders, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Prevention

How we know · 6 judgments

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 32 studies in Obesity by Hospices Civils de Lyon — 11 open to participants now, 12 under way, 1 of them phase 3. Obesity · Hospices Civils de Lyon.

Planned enrollment
15th of 23
50 · median 70
Started
2026
with 3 others
No phase
20 of 32
9 open now
Primary completion
2027-12
later than 8 of 11 live
Registered
29th of 32
by date

Among the 32 studies in Obesity by Hospices Civils de Lyon, this one is the 15th largest by planned enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2026, is one of 20 with no phase, reaches primary completion later than 8 of the 11 other live ones, and was the 29th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

11 of the 32 studies in Obesity by Hospices Civils de Lyon are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Obesity by Hospices Civils de Lyon, or all of them as a file.
02

Study summary

Obesity is a prevalent chronic disease affecting 17% of the French population. Treatment involves multiple factors, with pharmacotherapy playing an increasingly important role. GLP-1 receptor agonists (GLP1 RAs) are considered revolutionary in obesity treatment, with three approved molecules available in France: liraglutide, semaglutide, and tirzepatide. These treatments, combined with a healthy lifestyle, induce significant weight loss: 9% with liraglutide, 15% with semaglutide, and 20% with tirzepatide.

The most common adverse events (AEs) associated with GLP-1 RAs are gastrointestinal (GI) disorders, including nausea, vomiting, diarrhea, and abdominal pain. These AEs are dose-dependent and often decline over time. In phase 3 trials, semaglutide 2.4 mg showed higher rates of GI AEs compared to placebo, but most were mild to moderate and transient. GI AEs led to dose reduction or temporary treatment interruption in 12.5% of participants, with few permanent discontinuations.

Probiotics, are live microorganisms that benefit the host by improving gut microflora. Probiotics has been clinically proven to benefit gastrointestinal health. Probiotics may reduces symptoms of irritable bowel syndrome (IBS), improves gut barrier function, reduces inflammation, and decreases the incidence of C. difficile infection (CDI) in patients taking antibiotics.

Probiotics is therefore theorized to potentially reduce GI side effects associated with GLP-1 RA treatment for obesity.

Hypothesis Probiotics will prevent and limit the digestive disorders induced by GLP-1 R agonists, particularly during the dose escalation period. This would allow better digestive tolerance of the treatments, limiting the number of definitive treatment interruptions, facilitating compliance and dose escalation with a larger number of subjects at full dose and therefore with better systemic exposure to the compounds, a key factor in their effects on weight loss.

Read the detailed description

Obesity is a prevalent chronic disease affecting 17% of the French population. Treatment involves multiple factors, with pharmacotherapy playing an increasingly important role. GLP-1 receptor agonists (GLP1 RAs) are considered revolutionary in obesity treatment, with three approved molecules available in France: liraglutide, semaglutide, and tirzepatide. These treatments, combined with a healthy lifestyle, induce significant weight loss: 9% with liraglutide, 15% with semaglutide, and 20% with tirzepatide.

The most common adverse events (AEs) associated with GLP-1 RAs are gastrointestinal (GI) disorders, including nausea, vomiting, diarrhea, and abdominal pain. These AEs are dose-dependent and often decline over time. In phase 3 trials, semaglutide 2.4 mg showed higher rates of GI AEs compared to placebo, but most were mild to moderate and transient. GI AEs led to dose reduction or temporary treatment interruption in 12.5% of participants, with few permanent discontinuations.

Probiotics, are live microorganisms that benefit the host by improving gut microflora. Probiotics has been clinically proven to benefit gastrointestinal health. Probiotics may reduces symptoms of irritable bowel syndrome (IBS), improves gut barrier function, reduces inflammation, and decreases the incidence of C. difficile infection (CDI) in patients taking antibiotics.

Probiotics is therefore theorized to potentially reduce GI side effects associated with GLP-1 RA treatment for obesity.

Hypothesis Probiotics will prevent and limit the digestive disorders induced by GLP-1 R agonists, particularly during the dose escalation period. This would allow better digestive tolerance of the treatments, limiting the number of definitive treatment interruptions, facilitating compliance and dose escalation with a larger number of subjects at full dose and therefore with better systemic exposure to the compounds, a key factor in their effects on weight loss.

03

Conditions studied

  • Obesity &Amp; Overweight
  • Digestive Disorders

Keywords

  • GLP1 R-agonist
  • Probiotics
  • Quality of life
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient who is going to start a GLP-1 RA (semaglutide or tirzepatide) for weight management
  • Men or Women
  • ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 associated with one or more co-morbidities (arterial hypertension, sleep apnea, dyslipidemia, arthritis)
  • Between 18 and 75 years old
  • In the opinion of the investigator, the patient must have adequate support to comply with the entire study requirements as described in the protocol (e.g. transportation to and from trial site, ability to understand and fill the self-rating scales, drug compliance, availability to attend to the scheduled visits, etc…).
  • Patient who agrees to be included in the study and who signs the form
  • Female participants of must agree to use effective
  • Patient affiliated to a healthcare insurance plan

Exclusion criteria

Exclusion Criteria:

Criteria relating to the study population:

  • Patients under 18 years old
  • Patient with to semaglutide or tirzepatide according to the Summary of Product Characteristics (SPC).
  • Patients scheduled for bariatric surgery during the study period
  • Patients who have had bariatric surgery in the last 12 months
  • Patient with a current diagnosis of diabetes.
  • Patients with a current diagnosis of liver cirrhosis, short bowel syndrome or inflammatory bowel disease (IBD).
  • Patients with severely weakened immune system.
  • Clinically unstable medical disease, including cardiovascular, hepatic, renal, gastrointestinal, pulmonary, metabolic, endocrine, or other systemic disease.

Product criteria:

Patient with known allergy to the product of the study

Prohibited treatments :

Current associated treatments or used in the last 30 days: GLP-1 RA, Anti-obesity drugs (AOD), , Atypical neuroleptics, Antibiotics, Probiotics, Prebiotics

Regulatory criteria :

  • Persons deprived of their liberty by a judicial or administrative decision
  • Persons under psychiatric care
  • Persons admitted to a health or social institution for purposes other than research
  • Adults subject to a legal protection measure (guardianship, curatorship)
  • Persons not affiliated to a social security scheme or beneficiaries of a similar scheme
  • Subjects participating in other interventional research with an exclusion period still in progress at pre-inclusion
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Probiotics

    Obese subjects who are going to start a GLP-1 R-agonist (semaglutide or tirzepatide) as part of their weight management in routine clinical practice will received during 26 weeks 1 capsule a day every morning of probiotics that will begin 2 weeks before the initiation of semaglutide or tirzepatide treatment.

    Dietary Supplement: Probiotics (Natural product)

  • Placebo comparator
    Placebo

    Obese subjects who are going to start a GLP-1 R-agonist (semaglutide or tirzepatide) as part of their weight management in routine clinical practice will received during 26 weeks 1 capsule a day every morning of PLACEBO that will begin 2 weeks before the initiation of semaglutide or tirzepatide treatment.

    Other: Placebo

Interventions

  • Dietary supplementBiological ProductsStudies of Biological ProductsBiological Products pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will be instructed to daily take, during 26 weeks (that will begin 2 weeks before the initiation of semaglutide or tirzepatide treatment) one capsule of a probiotic with water at room temperature with the first meal. Dosage levels: 1 capsule Digestive Quality of life during the study will be assessed.

  • OtherPlacebo

    Participants will be instructed to daily take, during 26 weeks (that will begin 2 weeks before the initiation of semaglutide or tirzepatide treatment) one capsule of PLACEBO with water at room temperature with the first meal. Digestive Quality of life during the study will be assessed.

This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TirzepatideStudies of TirzepatideTirzepatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Assessment of the Limitation of the impairment in digestive quality of life during the dose escalation of GLP1-RA (semaglutide or tirzepatide)

    Assessment using partial GIQLI Score (5 items: 1,27,31,32,33 of the total GIQLI) in each GLP-1 RA group measured 4 weeks following the previous dose escalation, with the GLP1-RA dose standardized on a 0-1 scale. Item 1 for abdominal pain, Item 27 for dyspepsia, Item 31 for diarrhea, item 32 for constipation and Item 33 for nausea. For each item, 5 responses will be proposed to the patients and for each answer, a score ranging from 0 to 4 will be assigned The highest score is 20 and defines a more favorable health state

    Time frame: Every 5 weeks

Secondary outcomes

  1. Digestive quality of life

    Comparison between the probiotic group and placebo group in the whole population and in the subpopulation of subjects having reached the planned GLP-1 RA treatment dose at 24 weeks, according to the dose escalation design: Evolution of the partial GIQLI Scores (Questions 1,27,31,32,33). Item 1 for abdominal pain, Item 27 for dyspepsia, Item 31 for diarrhea, item 32 for constipation and Item 33 for nausea. For each item, 5 responses and for each answer, a score ranging from 0 to 4. The highest score is 20 and defines a more favorable health state

    Time frame: From baseline to 4, 8, 12, 16, 20 and 24 weeks of treatment

  2. Nausea

    Comparison of nausea between the probiotic group and placebo group in the whole population and in the subpopulation of subjects having reached the planned GLP-1 RA treatment dose at 24 weeks, according to the dose escalation design: Evolution of partial GIQLI score (question 33) of nausea score ranging from 0 to 4. 4 defines the more favourable score

    Time frame: From baseline to 4, 8, 12, 16, 20 and 24 weeks of treatment

  3. Dyspepsia

    Comparison of dyspepsia between the probiotic group and placebo group in the whole population and in the subpopulation of subjects having reached the planned GLP-1 RA treatment dose at 24 weeks, according to the dose escalation design: Evolution of partial GIQLI score (question 27) of dyspepsia score ranging from 0 to 4. 4 defines the more favourable score

    Time frame: From baseline to 4, 8, 12, 16, 20 and 24 weeks of treatment

  4. Diarrhea

    Comparison of diarrhea between the probiotics group and placebo group in the whole population and in the subpopulation of subjects having reached the planned GLP-1 RA treatment dose at 24 weeks, according to the dose escalation design: Evolution of partial GIQLI score (question 31) of diarrhea score ranging from 0 to 4. 4 defines the more favourable score

    Time frame: From baseline to 4, 8, 12, 16, 20 and 24 weeks of treatment

  5. Constipation

    Comparison of constipation between the probiotic group and placebo group in the whole population and in the subpopulation of subjects having reached the planned GLP-1 RA treatment dose at 24 weeks, according to the dose escalation design: Evolution of partial GIQLI score (question 32) of constipation score ranging from 0 to 4. 4 defines the more favourable score

    Time frame: From baseline to 4, 8, 12, 16, 20 and 24 weeks of treatment

  6. Abdominal pain

    Comparison of abdominal pain between the probiotic group and placebo group in the whole population and in the subpopulation of subjects having reached the planned GLP-1 RA treatment dose at 24 weeks, according to the dose escalation design: Evolution of partial GIQLI score (question 1) of abdominal pain score ranging from 0 to 4. 4 defines the more favourable score

    Time frame: From baseline to 4, 8, 12, 16, 20 and 24 weeks of treatment

  7. GLP-1 receptor agonist dosage

    Average GLP-1 RA dose

    Time frame: 4, 8, 12, 16, 20 and 24 weeks of intervention

  8. GLP1-RA dose escalation

    Proportion of patients having reached the planned GLP-1 RA treatment dose according to the dose escalation protocol at 4, 8, 12, 16, 20 and 24 weeks

    Time frame: 4, 8, 12, 16, 20 and 24 weeks of intervention

  9. GLP1-RA dose discontinuation/maintenance

    Proportion of patients who had to reduce or to interrupt definitively their GLP-1 RA treatment dose at 4, 8, 12, 16, 20 and 24 weeks

    Time frame: 4, 8, 12, 16, 20 and 24 weeks of intervention

  10. Weight loss

    Percent of weight change from baseline

    Time frame: 4, 8, 12, 16, 20 and 24 weeks of intervention

  11. Weight loss

    absolute change in body weight from baseline

    Time frame: 4, 8, 12, 16, 20 and 24 weeks of intervention

  12. Weight loss

    Rate of patients achieving a body weight reduction of ≥5%, ≥10%, ≥15%

    Time frame: 4, 8, 12, 16, 20 and 24 weeks of intervention

  13. Quality of life assessed with GIQLI questionnaire

    This questionnaire consists of 36 items exploring 5 dimensions or subscales: symptoms, physical condition, emotions, social integration and the effect of any medical treatment. For each item, 5 responses will be proposed to the patients and for each answer, a score ranging from 0 to 4 (highest score = 144) will be assigned. A high score defines a more favorable health state.

    Time frame: baseline, 12 and 24 weeks of treatment

  14. Quality of life assessed with SF36 questionnaire

    This questionnaire taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/tiredness, and general health perceptions. It also includes a single item that provides an indication of a perceived change in health

    Time frame: baseline, 12 and 24 weeks of treatment

  15. Fat mass

    Measurement of fat mass will explore the body composition. Results will be expressed in kg and %

    Time frame: Baseline, before implementation of GLP1-RA, 12 and 24 weeks of treatment

  16. Lean mass

    Measurement of lean mass will explore the body composition. Results will be expressed in kg and %

    Time frame: Baseline, before implementation of GLP1-RA, 12 and 24 weeks of treatment

  17. Skeletal muscle mass

    Measurement of skeletal muscle mass will explore the body composition. Results will be expressed in kg and %

    Time frame: Baseline, before implementation of GLP1-RA, 12 and 24 weeks of treatment

  18. Adverse Events

    The safety will be assessed by the Number of adverse events, linked or not to the study product

    Time frame: After 4, 8, 12, 16, 20 and 24 weeks of treatment.

  19. Severe Adverse Events

    The safety will be assessed by the number of severe adverse events, linked or not to the study product

    Time frame: After 4, 8, 12, 16, 20 and 24 weeks of treatment.

  20. Intestinal microbiota

    Fecal microbiota composition

    Time frame: Baseline and 24 weeks of treatment

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2027, 16 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 16 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2025
First posted
Oct 8, 2025
StartActual
Aug 5, 2026
Primary completionEst.
Dec 5, 2027
CompletionEst.
Aug 5, 2028
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07213323
Responsible party
Sponsor
First posted
Oct 8, 2025
Start date
Aug 5, 2026
Primary completion
Dec 5, 2027 (estimated)
Completion
Aug 5, 2028 (estimated)
Last update
Aug 19, 2026

Study contacts

Emmanuel DISSE, PUPH
Contact
Emmanuel.disse@chu-lyon.fr
+33478861484
Dominique DELAUNAY, PhD
Contact
Dominique.delaunay@chu-lyon.Fr
+33472110064
Emmanuel DISSE, PUPH
principal investigator · Hospices Civils de Lyon

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Biological Products

Start the discussion